一种类固醇模拟物通过阻断光滑化胆固醇的胆固醇化来抑制刺的通路
Yuan-Bin Liu1, Li-Ming He2, Ming Sun1
1Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan 430000, China.
Cell chemical biology
|March 5, 2024
概括
一种名为Q29的新药准了光滑化 (SMO) 氨酸丰富域 (CRD),以抑制刺 (Hh) 途径. 这种方法克服了对当前SMO抑制剂的耐药性,并为治疗Hh驱动癌症提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 刺 (Hh) 信号通路对细胞增殖和瘤产生至关重要,使其成为抗癌药物开发的目标.
- 目前的Hh通路抑制剂主要向七个跨膜 (7TM) 区域的光滑化 (SMO),但获得的耐药性是一个重要的临床挑战.
研究的目的:
- 为了确定Hh信号通路的新型抑制剂,可以克服现有的药物耐药性机制.
- 为了研究一种类固醇模拟物,Q29,作为一种潜在的治疗剂,针对不同的SMO领域.
主要方法:
- 醇模拟物Q29.9的识别和特征.
- 通过测量其与SMO氨酸丰富域 (CRD) 的结合及其对胆固醇化的影响,评估Q29对Hh通路的抑制作用.
- 评估Q29在抑制Hh信号依赖细胞增殖和脑髓母细胞瘤生长方面的疗效,单独或与vismodegib结合使用.
- 测试Q29克服SMO突变媒介的耐药性和抑制瘤性SMO变体的能力.
主要成果:
- 固醇模拟Q29通过与SMOCRD结合并阻断胆固醇化来抑制Hh通路.
- Q29有效地抑制了依赖Hh信号的增殖和脑髓母细胞瘤的生长.
- Q29证明了与vismodegib的添加效应,重要的是,克服了由SMO突变引起的SMO-7TM抑制剂的耐药性,也抑制了瘤性SMO变异.
结论:
- 用像Q29这样的抑制剂向SMO-CRD代表了治疗Hh通路驱动癌症的新有效策略.
- Q29提供了一个有前途的治疗途径,特别是对于那些对当前SMO-7TM抑制剂耐药的患者.
相关概念视频
02:33Hedgehog Signaling Pathway
7.4K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.4K
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
01:16TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
565
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
565